The University of Siena PhD Course in
Genetics, Oncology and Clinical Medicine


PhD Graduate

Iris Maria FORTE 

PhD Program years: 2008 - 2012







PUBLICATIONS DURING THE PHD PROGRAM
  1. HOX D13 expression across 79 tumor tissue types.
    Cantile M, Franco R, Tschan A, Baumhoer D, Zlobec I, Schiavo G, Forte I, Bihl M, Liguori G, Botti G, Tornillo L, Karamitopoulou-Diamantis E, Terracciano L, Cillo C.
    Int J Cancer. 2009 Oct 1;125(7):1532-41.

  2. Rb family proteins in gastric cancer (review).
    Cito L, Pentimalli F, Forte I, Mattioli E, Giordano A.
    Oncol Rep. 2010 Dec;24(6):1411-8.

  3. Parallel determination of NeuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers.
    Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, Zlobec I, Salzano L, Botti G, Gidaro S, Terracciano L, Cillo C.
    Int Braz J Urol. 2011 Jan-Feb;37(1):57-66.

  4. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.
    Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D'Urso V, Grilli B, Botta M, Giordano A, Pentimalli F.
    Oncogene. 2011 Jul 25.

  5. Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
    Cozzi M, Giorgi F, Marcelli E, Pentimalli F, Forte IM, Schenone S, D'urso V, De Falco G, Botta M, Giordano A, Indovina P.
    Cell Cycle. 2012 Mar 1;11(5).

  6. Modeling human osteosarcoma in mice through 3AB-OS cancer stem cell xenografts.
    Di Fiore R, Guercio A, Puleio R, Di Marco P, Drago-Ferrante R, D'Anneo A, De Blasio A, Carlisi D, Di Bella S, Pentimalli F, Forte IM, Giordano A, Tesoriere G, Vento R.
    J Cell Biochem. 2012 Nov;113(11):3380-92.

  7. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F.
    Cell Cycle. 2014;13(4):652-65. doi: 10.4161/cc.27546.

  8. Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A.
    Cancer Biol Ther. 2014 Apr;15(4):380-8. doi: 10.4161/cbt.27623.

  9. Antineoplastic activity of povidone-iodine on different mesothelioma cell lines: results of in vitro study.
    Fiorelli A, Pentimalli F, D'Urso V, Di Marzo D, Forte IM, Giordano A, Di Domenico M, Accardo M, Di Serio U, Santini M.
    Eur J Cardiothorac Surg. 2014 Jun;45(6):993-1000.

  10. MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells.
    Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D'Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G, Giordano A, Vento R.
    Int J Oncol. 2014 Nov;45(5):2013-23.

  11. pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer.
    Cito L, Indovina P, Forte IM, Pentimalli F, Di Marzo D, Somma P, Barone D, Penon A, Penon D, Ceccherini E, Micheli P, Saragoni L, Di Domenico M, Feola A, Roviello F, Mattioli E, Giordano GG,Giordano A.
    J Cell Physiol. 2015 Apr;230(4):802-5.

  12. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
    Ceccherini E, Indovina P, Zamperini C, Dreassi E, Casini N, Cutaia O, Forte IM, Pentimalli F, Esposito L, Polito MS, Schenone S, Botta M, Giordano A.
    J Cell Biochem. 2015 May;116(5):856-63.

  13. SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
    Casini N, Forte IM, Mastrogiovanni G, Pentimalli F, Angelucci A, Festuccia C, Tomei V, Ceccherini E, Di Marzo D, Schenone S, Botta M, Giordano A, Indovina P.
    Oncotarget. 2015 May 20;6(14):12421-35.
ABSTRACTS OF CONFERENCE DURING THE PHD PROGRAM


1. A miRNA expression profiling identifies mir-14 as a key player in human malignant pleural mesothelioma (Congresso internazionale GOIM, Brindisi, Italia, 20-23/6/2010)PUB

2. Small molecules mimicking the spa310 peptide from the spacer region of pRB2/p130 as potential anticancer agents (Fifth Annual Scientific Conference ITT, Il Borro. San Giustino Valdarno ,Italia, 1/7/2010)

3. Studi preliminari dell’espressione di pRb2/p130 e della Ciclina A2 nel carcinoma gastrico (Update in tema di Anatomia patologia e ricaduta clinica, Imperial Hotel Tramontano , Sorrento 27-29 Maggio 2011)

4. A selective cdk inhibitor mimicking the spa310 as a potential anticancer agent.( 130 Congresso Nazionale del Goim “Trattamenti innovative in Oncologia”. Bari 19-22 Giugno 2011)

5. Pharmacological targeting of p53 effectively induces apoptosis in malignant mesothelioma cell lines. (130 Congresso Nazionale del Goim “Trattamenti innovative in Oncologia”. Bari 19-22 Giugno 2011)

6. New SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.(130 Congresso Nazionale del Goim “Trattamenti innovative in Oncologia”. Bari 19-22 Giugno 2011)

7. New SCR inhibitors induce p27- mediated apoptosis in mesotelioma cell lines (ACCR 10 2nd Annual Meeting 2011) 

ACTIVITY DURING THE PHD PROGRAM

TRAINING PERIOD ABROAD
  • Hosting Institution Name
    Location
    Period dates

  • Hosting Institution Name
    Location
    Period dates